Kyverna Therapeutics (KYTX)

• Market cap: $113M
• 1 day: 0.77%
• 5 days: 3.97%
• 1 month: -12.96%
• 3 months: -42.92%
• 6 months: -63.25%
• Year to date: -33.16%
• 1 year: -91.12%
• 5 years: -91.27%
• 10 years: -91.27%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Employees: 119

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,960% more call options, than puts

Call options by funds: $206K | Put options by funds: $10K

154% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 13

3.79% less ownership

Funds ownership: 70.66% [Q3] → 66.87% (-3.79%) [Q4]

6% less funds holding

Funds holding: 93 [Q3] → 87 (-6) [Q4]

14% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 28

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

28% less capital invested

Capital invested by funds: $150M [Q3] → $108M (-$41.8M) [Q4]